✦ LIBER ✦

P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer

✍ Scribed by M. Colozza; G. Bisagni; A.M. Mosconi; S. Gori; C. Boni; A. Rosa Bian; R. Sabbatini; A. Frassoldati; R. Passalacqua; C. Rodinò; E. Rondini; R. Algeri; S. Di Sarra; M. Bacchi; M. Tonato; G. Cocconi

Book ID: 117665521
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 151 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)89303-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epirubicin versus CMF as adjuvant therap

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study

✍ M Colozza; G Bisagni; A.M Mosconi; S Gori; C Boni; R Sabbatini; A Frassoldati; R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 191 KB

C-ERB-B2 expression as a predictor of ou

C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients

✍ M. Colozza; S. Gori; A.M. Mosconi; E. Bucciarelli; G. Bisagni; C. Rodinò; A.Rosa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB

76 Adjuvant four cycles of epirubicin an

76 Adjuvant four cycles of epirubicin and cyclophosphamide with radiation therapy in operated stage II–III breast cancer

✍ M. Ünsal; A. Yöney; F. Erman 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Comparison of adjuvant therapy with tamo

Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5

✍ R. Jakesz; H. Hausmaninger; H. Samonigg; E. Kubista; D. Depisch; M. Fridrik; M. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 118 KB

P107 The ‘ZEBRA’ study: ‘Zoladex’ (goser

P107 The ‘ZEBRA’ study: ‘Zoladex’ (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less

✍ W. Jonat; M. Kaufmann; R. Blamey; T. Sheldon 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Gemcitabine, epirubicin and docetaxel as

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study

✍ A. Schneeweiss; J. Huober; H.-P. Sinn; D. von Fournier; C. Rudlowski; F. Belderm 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 269 KB